Influence of Telomere length on the achievement of deep molecular response with Imatinib in chronic myeloid Leukemia patients
Estrada Barreras, Natalia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Beier, Fabian (Uniklinik RWTH Aachen University)
García, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Morales, Cristian (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Boque, Concepcion (Institut Català d'Oncologia)
Sagüés, Miguel (Institut Català d'Oncologia)
Ferreira, Monica S. Ventura (Uniklinik RWTH Aachen University)
Vallansot, Rolando (Institut Català d'Oncologia)
Marcé, Silvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Cabezón, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Brümmendorf, Tim H. (Uniklinik RWTH Aachen University)
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)

Data:	2021
Resum:	Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation approaches. Few biological factors at diagnosis have been associated with this level of response. Telomere length (TL) in peripheral blood cells of patients with CML has been related to disease stage, response to therapy and disease progression, but little is known about its role on DMR. In this study, we analyzed if age-adjusted TL (referred as "delta-TL") at diagnosis of chronic phase (CP)-CML might correlate with the achievement of DMR under first-line imatinib treatment. TL from 96 CP-CML patients had been retrospectively analyzed at diagnosis by monochrome multiplex quantitative PCR. We observed that patients with longer age-adjusted telomeres at diagnosis had higher probabilities to achieve DMR with imatinib than those with shortened telomeres (P = 0. 035 when delta-TL was studied as a continuous variable and P = 0. 047 when categorized by the median). Moreover, patients carrying long telomeres also achieved major molecular response significantly earlier (P = 0. 012). This study provides proof of concept that TL has a role in CML biology and when measured at diagnosis of CP-CML could help to identify patients likely to achieve DMR to first-line imatinib treatment.
Ajuts:	Ministerio de Economía, Industria y Competitividad PI16/01200
Nota:	Fundació Carreras
Nota:	This work was in part supported by a grant from Instituto de Salud Carlos III through the project "PI16/01200" (Co-funded by European Regional Development Fund/European Social Fund "A way to make Europe"/"Investing in your future") as well as by the grant "Bolsa de ayuda económica para la innovación científica" and the grant "Becas de Investigación" both from Fundación Española de Hematología y Hemoterapia (FEHH).
Nota:	This work was in part supported by a grant from Instituto de Salud Carlos III through the project "PI16/01200" (Co-funded by European Regional Development Fund/European Social Fund "A way to make Europe"/"Investing in your future") as well as by the grant "Bolsa de ayuda economica para la innovacion cientifica" and the grant "Becas de Investigacion" both from Fundacion Espanola de Hematologia y Hemoterapia (FEHH).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	HemaSphere, Vol. 5 Núm. 12 (30 2021) , p. e657, ISSN 2572-9241

DOI: 10.1097/HS9.0000000000000657
PMID: 34853825

7 p, 619.6 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats